Renal Cell Carcinoma
Clinical research in renal cell carcinoma centers on treatment strategies for disease that has progressed after prior immune checkpoint inhibitor-based therapy. The sponsor’s studies in this area examine combinations involving tivozanib and nivolumab, with attention to progression-free survival and overall survival in advanced kidney cancer.
- Tivozanib and nivolumab
- Progression-free survival
- Advanced renal cancer
The focus includes patients with previously treated metastatic renal cell carcinoma and the evaluation of combination therapy in later-line disease.
Head and Neck Squamous Cell Carcinoma
Research in head and neck squamous cell carcinoma is directed toward recurrent or metastatic HPV-negative disease. The sponsor is studying ficlatuzumab with cetuximab in this setting, with outcomes centered on overall survival for adults whose cancer has returned or spread.
- HPV-negative recurrent disease
- Ficlatuzumab and cetuximab
- Overall survival
The therapeutic interest extends to metastatic head and neck cancer and treatment approaches used after disease recurrence.
